$PODD
INSULET CORP

2014 Q4 Form 10-Q Financial Statement

#000114519714000055 Filed on November 05, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $58.36M $60.03M $61.10M
YoY Change -14.84% -1.76% 11.6%
Cost Of Revenue -$5.300M $36.94M $33.71M
YoY Change -114.93% 9.6% 11.02%
Gross Profit $33.12M $33.74M $27.40M
YoY Change 0.3% 23.17% 12.32%
Gross Profit Margin 56.74% 56.21% 44.83%
Selling, General & Admin $12.10M $33.76M $38.94M
YoY Change -54.17% -13.3% 48.04%
% of Gross Profit 36.54% 100.05% 142.13%
Research & Development $7.300M $7.158M $5.771M
YoY Change 14.06% 24.03% -12.01%
% of Gross Profit 22.04% 21.21% 21.07%
Depreciation & Amortization $3.050M $3.070M $3.100M
YoY Change 3.39% -0.97% 19.69%
% of Gross Profit 9.21% 9.1% 11.32%
Operating Expenses $19.30M $40.92M $44.71M
YoY Change -41.16% -8.48% 36.05%
Operating Profit $13.82M -$2.876M -$17.31M
YoY Change 6238.53% -83.39% 104.38%
Interest Expense -$3.000M -$3.700M $100.0K
YoY Change 3.45% -3800.0% -102.56%
% of Operating Profit -21.71%
Other Income/Expense, Net -$100.0K -$7.948M -$3.972M
YoY Change 100.1% 1.38%
Pretax Income -$1.900M -$10.82M -$21.29M
YoY Change -29.63% -49.15% 71.81%
Income Tax -$100.0K $21.00K $5.000K
% Of Pretax Income
Net Earnings -$5.400M -$10.85M -$21.29M
YoY Change 116.0% -49.06% 71.46%
Net Earnings / Revenue -9.25% -18.07% -34.84%
Basic Earnings Per Share
Diluted Earnings Per Share -$96.09K -$193.5K -$390.8K
COMMON SHARES
Basic Shares Outstanding 56.08M shares 55.88M shares 54.42M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $151.2M $146.4M $153.9M
YoY Change 1.0% -4.87% 142.74%
Cash & Equivalents $151.2M $146.4M $153.9M
Short-Term Investments
Other Short-Term Assets $4.000M $3.400M $5.900M
YoY Change -32.2% -42.37% 5.36%
Inventory $11.45M $9.662M $5.395M
Prepaid Expenses
Receivables $35.24M $47.15M $34.47M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $208.2M $206.6M $199.7M
YoY Change 5.04% 3.47% 74.79%
LONG-TERM ASSETS
Property, Plant & Equipment $36.94M $36.58M $31.40M
YoY Change 14.17% 16.51% 26.05%
Goodwill $37.40M $37.54M $37.54M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $294.0K $5.493M $1.721M
YoY Change -83.89% 219.17% -26.23%
Total Long-Term Assets $88.99M $94.58M $89.81M
YoY Change -0.86% 5.32% 0.76%
TOTAL ASSETS
Total Short-Term Assets $208.2M $206.6M $199.7M
Total Long-Term Assets $88.99M $94.58M $89.81M
Total Assets $297.2M $301.2M $289.5M
YoY Change 3.2% 4.04% 42.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.58M $17.73M $15.12M
YoY Change -35.02% 17.26% -6.78%
Accrued Expenses $18.85M $25.21M $30.02M
YoY Change -3.22% -16.0% 68.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.400M $4.000M $0.00
YoY Change -100.0%
Total Short-Term Liabilities $44.30M $47.76M $48.29M
YoY Change 4.54% -1.1% -2.12%
LONG-TERM LIABILITIES
Long-Term Debt $164.0M $167.4M $111.1M
YoY Change 44.32% 50.67% 9.46%
Other Long-Term Liabilities $2.774M $2.580M $2.567M
YoY Change 42.77% 0.51% 24.01%
Total Long-Term Liabilities $166.8M $170.0M $113.7M
YoY Change 44.29% 49.54% 9.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.30M $47.76M $48.29M
Total Long-Term Liabilities $166.8M $170.0M $113.7M
Total Liabilities $213.4M $220.9M $168.1M
YoY Change 30.6% 31.41% 9.9%
SHAREHOLDERS EQUITY
Retained Earnings -$578.0M -$572.6M -$524.0M
YoY Change 9.78% 9.27% 11.17%
Common Stock $56.00K $56.00K $55.00K
YoY Change 1.82% 1.82% 14.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $83.83M $80.34M $121.4M
YoY Change
Total Liabilities & Shareholders Equity $297.2M $301.2M $289.5M
YoY Change 3.2% 4.04% 42.34%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$5.400M -$10.85M -$21.29M
YoY Change 116.0% -49.06% 71.46%
Depreciation, Depletion And Amortization $3.050M $3.070M $3.100M
YoY Change 3.39% -0.97% 19.69%
Cash From Operating Activities $4.610M $4.820M $3.700M
YoY Change -230.97% 30.27% -207.25%
INVESTING ACTIVITIES
Capital Expenditures -$2.640M -$3.100M -$1.820M
YoY Change -5.38% 70.33% -61.19%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.640M -$3.100M -$1.820M
YoY Change -5.38% 70.33% -61.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.840M -30.88M 1.090M
YoY Change 33.33% -2933.03% -23.78%
NET CHANGE
Cash From Operating Activities 4.610M 4.820M 3.700M
Cash From Investing Activities -2.640M -3.100M -1.820M
Cash From Financing Activities 2.840M -30.88M 1.090M
Net Change In Cash 4.810M -29.16M 2.970M
YoY Change -215.07% -1081.82% -144.26%
FREE CASH FLOW
Cash From Operating Activities $4.610M $4.820M $3.700M
Capital Expenditures -$2.640M -$3.100M -$1.820M
Free Cash Flow $7.250M $7.920M $5.520M
YoY Change -1093.15% 43.48% 345.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
17726000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
19359000 USD
CY2013Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
40200000 USD
CY2014Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
53567000 USD
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
47145000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
33067000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19478000 USD
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25214000 USD
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P7Y
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
651067000 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
652909000 USD
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9600000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9800000 USD
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3000000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18200000 USD
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
7133000 USD
CY2014Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6422000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
7958000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
6431000 USD
CY2013Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2447000 USD
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1694000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-66000 USD
CY2014Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1548000 USD
CY2014Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
277000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
615000 USD
CY2013Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
146000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
443000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8397000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8401000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3100000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3800000 USD
CY2014Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
900000 USD
CY2013Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 USD
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8715231 shares
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6663318 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6663318 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8715231 shares
CY2014Q3 us-gaap Assets
Assets
301197000 USD
CY2013Q4 us-gaap Assets
Assets
287955000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
198198000 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
206613000 USD
CY2013Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2637000 USD
CY2014Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3990000 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
9021000 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
1474000 USD
CY2014Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
3095000 USD
CY2013Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
5390000 USD
CY2014Q3 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
8187000 USD
CY2014Q3 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
4068000 USD
CY2014Q3 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
2408000 USD
CY2014Q3 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
1102000 USD
CY2014Q3 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
7085000 USD
CY2014Q3 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1711000 USD
CY2014Q3 us-gaap Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
400000 USD
us-gaap Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
1000000 USD
CY2013Q3 us-gaap Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
100000 USD
us-gaap Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
100000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149727000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
146372000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
153905000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
99168000 USD
CY2013Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33708000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57293000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
123140000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
128308000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3355000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
96612000 USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54870424 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56040361 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54870424 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56040361 shares
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
56000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
55000 USD
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.26
CY2013 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.36
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4517000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
259920 shares
CY2013 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
CY2013 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y5M15D
CY2013 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.3800
CY2013 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0056
CY2013Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
30099000 USD
CY2014Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
5168000 USD
CY2013Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1414000 USD
CY2014Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
15000 USD
CY2013Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
25000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
83000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
79000 USD
CY2014Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36943000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
109544000 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
171000 USD
CY2013Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-20000 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
59000 USD
CY2014Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
6000 USD
CY2013Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
26523 shares
CY2013Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
620122 shares
CY2014Q3 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
348535 shares
CY2014Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
33832000 USD
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
900000 USD
CY2014Q3 us-gaap Deferred Revenue
DeferredRevenue
800000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
900000 USD
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
834000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9168000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8859000 USD
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.83
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
27700000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
17927000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
14860000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
4151000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3251000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
910000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1806000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2190000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2665000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
14973000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18040000 USD
CY2011 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
32900000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-23203000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-325000 USD
CY2013Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2014Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-4260000 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18890000 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23530000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
52661000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50525000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
37536000 USD
CY2014Q3 us-gaap Goodwill
Goodwill
37536000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2013Q3 us-gaap Gross Profit
GrossProfit
27395000 USD
us-gaap Gross Profit
GrossProfit
106615000 USD
us-gaap Gross Profit
GrossProfit
79383000 USD
CY2014Q3 us-gaap Gross Profit
GrossProfit
38042000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-42220000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-45962000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-21285000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10824000 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
254000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
138000 USD
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16747000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5113000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4878000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-9472000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
198000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
637000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
700000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1401000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1242000 USD
CY2014Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
3043000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
11507000 USD
CY2013Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
3999000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
12645000 USD
CY2013Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7394000 USD
CY2014Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
9028000 USD
CY2014Q3 us-gaap Inventory Net
InventoryNet
9662000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
9464000 USD
CY2013Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
399000 USD
CY2014Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
634000 USD
CY2014Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
0 USD
CY2013Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1671000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
92000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
91000 USD
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
32000 USD
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
27000 USD
CY2014Q3 us-gaap Liabilities
Liabilities
220857000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
163358000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
287955000 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
301197000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
42374000 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
47764000 USD
CY2014Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
167418000 USD
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
113651000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1185000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
94263000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4517000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8853000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6866000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4313000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of the Business</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is primarily engaged in the development, manufacturing and sale of its proprietary OmniPod Insulin Management System (the &#8220;OmniPod System&#8221;), an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes. The OmniPod System is the only commercially-available insulin infusion system of its kind. The OmniPod System features a unique disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the handheld, wireless Personal Diabetes Manager (&#8220;PDM&#8221;). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">42</font><font style="font-family:inherit;font-size:10pt;"> inches of tubing. In contrast, the OmniPod System features two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. </font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2011, the Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, &#8220;Neighborhood Diabetes&#8221;) in order to expand the Company&#8217;s full suite diabetes management product offerings and obtain access to a larger number of insulin dependent patients. Through Neighborhood Diabetes, the Company is able to provide customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and has the ability to process claims as either durable medical equipment or through pharmacy benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company began commercial sale of the OmniPod System in the United States in October 2005. The Company has also expanded the availability of the OmniPod System internationally through its partnerships with Ypsomed Distribution AG (&#8220;Ypsomed&#8221;) and GlaxoSmithKline (&#8220;GSK&#8221;). In August 2011, the Company received CE Mark approval, and in December 2012, the Company received 510(k) clearance for the new OmniPod System from the FDA. The Company began selling its new OmniPod System in 2013. The new OmniPod System is more than one-third smaller and one-quarter lighter than the original model, while maintaining the same features and operating capabilities.</font></div></div>
us-gaap Net Income Loss
NetIncomeLoss
-42474000 USD
us-gaap Net Income Loss
NetIncomeLoss
-46100000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-21290000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-10845000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-35920000 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3972000 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7948000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12879000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Operating Expenses
OperatingExpenses
108724000 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
44708000 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
40918000 USD
us-gaap Operating Expenses
OperatingExpenses
116657000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10042000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-29341000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2876000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17313000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
16982000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2096000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2144000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2139000 USD
CY2013Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
702000 USD
CY2014Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
566000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2565000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
8573000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8853000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2057000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
8249000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
297000 USD
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2511000 USD
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0 USD
CY2013Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
1351000 USD
CY2014Q3 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
0 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1825000 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5493000 USD
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2580000 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1943000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1302000 USD
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-677000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3434000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5940000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
99164000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6877000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
194576000 USD
CY2013Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3090000 USD
CY2014Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2535000 USD
CY2013Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2809000 USD
CY2012Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1992000 USD
CY2013Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2401000 USD
CY2014Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2505000 USD
CY2014Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
977000 USD
CY2013Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1173000 USD
CY2013Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1917000 USD
CY2014Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1558000 USD
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1954000 USD
CY2014Q3 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
596000 USD
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
1139000 USD
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
2771000 USD
CY2013Q3 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
1110000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32356000 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36582000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
3942000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2669000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2000000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
189521000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2174000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
336000 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7158000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15341000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5771000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20614000 USD
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1300000 USD
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-526525000 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-572625000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
216159000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
178551000 USD
CY2014Q3 us-gaap Sales Revenue Net
SalesRevenueNet
74985000 USD
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
61103000 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53786974 shares
CY2013Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
97800000 USD
podd Allocationtoequityforconversionforthe2 Notes
Allocationtoequityforconversionforthe2Notes
0 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
506757 shares
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
80340000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
124597000 USD
CY2014Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates in Preparation of Financial Statements</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, accounts receivable, inventories, goodwill, deferred revenue, debt instruments, and equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.</font></div></div>
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54458364 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55819242 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55447414 shares
CY2013Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15407000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
43382000 USD
CY2014Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14870000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
42858000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
18247000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
9800000 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2538436 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
979868 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
13877000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
32565 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
25055000 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1549211 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1828613 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.62
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.46
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
24393000 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1448611 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
13.16
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
27.43
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
42.11
CY2013Q4 us-gaap Share Price
SharePrice
37.10
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
19801000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y7M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y0M0D
podd Allocationtoequityforconversionforthe2 Notes
Allocationtoequityforconversionforthe2Notes
35638000 USD
CY2013 podd Capital Leasesof Lessee Contingent Rentals Effective Interest Rate
CapitalLeasesofLesseeContingentRentalsEffectiveInterestRate
0.17
podd Changein Fair Valueof Call Option Feature
ChangeinFairValueofCallOptionFeature
1400000 USD
CY2014Q3 podd Changein Fair Valueof Call Option Feature
ChangeinFairValueofCallOptionFeature
800000 USD
CY2013Q3 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
1347000 USD
podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
4356000 USD
CY2014Q3 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
962000 USD
podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
3583000 USD
CY2013Q4 podd Fair Value Assumption Bond Call Strike Price
FairValueAssumptionBondCallStrikePrice
100.00
CY2013 podd Fair Value Assumption Conversion Price
FairValueAssumptionConversionPrice
26.20
CY2013 podd Fair Value Assumption Coupon Rate
FairValueAssumptionCouponRate
0.0375
CY2013 podd Fair Value Assumptions Bond Yield
FairValueAssumptionsBondYield
0.0861
podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
16722000 USD
podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
3861000 USD
CY2013Q3 podd Interestand Other Expense Total
InterestandOtherExpenseTotal
3940000 USD
CY2014Q3 podd Interestand Other Expense Total
InterestandOtherExpenseTotal
7047000 USD
podd Interestand Other Expense Total
InterestandOtherExpenseTotal
33832000 USD
podd Interestand Other Expense Total
InterestandOtherExpenseTotal
13082000 USD
CY2014Q3 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
2 customer
CY2013Q4 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
2 customer
CY2014Q3 podd Number Of Financial Institution
NumberOfFinancialInstitution
2 location
CY2014Q3 podd Number Of Inches Of Tubing In Conventional Insulin Pump
NumberOfInchesOfTubingInConventionalInsulinPump
42 in
CY2013Q4 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
CY2014Q3 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
podd Product Warranty Term
ProductWarrantyTerm
P4Y
CY2013 podd Repayment Periodfor Capital Lease Obligations
RepaymentPeriodforCapitalLeaseObligations
P36M
podd Return Period
ReturnPeriod
P45D
podd Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitures
0.16
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001145197
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56081464 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
INSULET CORP
dei Trading Symbol
TradingSymbol
PODD

Files In Submission

Name View Source Status
0001145197-14-000055-index-headers.html Edgar Link pending
0001145197-14-000055-index.html Edgar Link pending
0001145197-14-000055.txt Edgar Link pending
0001145197-14-000055-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
podd-20140930.xml Edgar Link completed
podd-20140930.xsd Edgar Link pending
podd-20140930_cal.xml Edgar Link unprocessable
podd-20140930_def.xml Edgar Link unprocessable
podd-20140930_lab.xml Edgar Link unprocessable
podd-20140930_pre.xml Edgar Link unprocessable
podd-2014x09x30_10xq.htm Edgar Link pending
podd-ex1010_20140930x10q.htm Edgar Link pending
podd-ex1011_20140930x10q.htm Edgar Link pending
podd-ex1012_20140930x10q.htm Edgar Link pending
podd-ex1013_20140930x10q.htm Edgar Link pending
podd-ex1014_20140930x10q.htm Edgar Link pending
podd-ex101_20140930x10q.htm Edgar Link pending
podd-ex102_20140930x10q.htm Edgar Link pending
podd-ex103_20140930x10q.htm Edgar Link pending
podd-ex104_20140930x10q.htm Edgar Link pending
podd-ex105_20140930x10q.htm Edgar Link pending
podd-ex106_20140930x10q.htm Edgar Link pending
podd-ex107_20140930x10q.htm Edgar Link pending
podd-ex108_20140930x10q.htm Edgar Link pending
podd-ex109_20140930x10q.htm Edgar Link pending
podd-ex311_20140930x10q.htm Edgar Link pending
podd-ex312_20140930x10q.htm Edgar Link pending
podd-ex321_20140930x10q.htm Edgar Link pending
podd_ex1015x20140903-10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending